Tag:

Eisai

Latest Headlines

Latest Headlines

Takeda and Orexigen make nice and say Contrave collaboration back on track

Presumably hands were shaken and lawyers and executives read the fine print, putting a collaboration on anti-obesity drug Contrave between Japan's Takeda Pharmaceuticals and San Diego-based Orexigen Therapeutics back on track after a tussle broke out in May over the termination of a trial that opened up other issues in the partnership.

Eisai's launch for 'crown jewel' Lenvima tracking better than execs expected

Eisai has struggled since falling off the patent cliff in 2010, when its blockbuster Alzheimer's med Aricept lost patent protection and sales took a hit. The company is looking to new meds to add salve to the wound, and a better-than-expected launch for its cancer hopeful Lenvima could be exactly what the doctor ordered.

New obesity meds 'pretty safe,' but some side effects bear watching: AdverseEvents

An analysis by AdverseEvents shows the new generation of obesity meds are holding their own, safety-wise. Still, postmarketing data flag some serious cardiovascular and neuropsychiatric side effects that are worth monitoring, the healthcare informatics firm says.

Eisai turns North Carolina facility over to Biogen as it continues its cost-cutting

Eisai has been whittling down its U.S. workforce as part of broader cost-cutting moves in the face of a tough patent cliff go. Now the Japanese drugmaker will trim another 135 people from its payroll with the sale of a manufacturing facility in North Carolina to drug development partner Biogen.

Brutal honesty in drug marketing? For obesity meds, it's key to avoiding the 'magic pill' trap

Dieting and exercise to lose weight is more effective when done with support--and weight-loss drugmakers have taken that to heart in marketing their treatments. But according to a recent Journal of Public Policy & Marketing article, lifestyle support isn't enough. Drugmakers may want to look to their advertising pitches, too.

Leading Japan drug firms team up with AZ on parasitic disease research

Japan's Eisai, Shinogi and Takeda Pharmaceutical have teamed up with U.K.-based AstraZeneca on a broad R&D effort to find treatments for insect-borne parasitic diseases Chagas and leishmaniasis.

Eisai predicts long-awaited operating profit rise for fiscal 2015

It's been a hard fall off the patent cliff for Eisai, but after 5 long years, the company says it sees its operating profit climbing in its next fiscal year.

Eisai to boost Indian API production to cut costs

Japan's Eisai, which is trying to cut costs worldwide, says it will produce more of its active pharmaceutical ingredients (APIs) at its facilities in India. The company merged two units in India in preparation. It also intends to try to sell more generic drugs.

Japan's Eisai makes moves for Indian API manufacturing in further cost trimming

Beginning in a year or two, Eisai plans to make major active pharmaceutical ingredients for generics at its Elmed Eisai state-of-the-art plants in India and import them to Japan, part of broader recent restructuring efforts by the company to trim costs.

Japan's Eisai, Glenmark settle on Banzel patent dispute

Eisai said it and Glenmark reached a settlement of the Japan drugmaker's U.S. suit for patent infringement of its Banzel (rufinamide) epilepsy drug.